ReviewNature reviews. Cardiology2025
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches.
Review in Nature reviews. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of resina draconis as an adjuvant therapy for diabetic foot ulcer: a meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2026Pooled it
- Diabetes mellitus and mortality in patients admitted to ICU with sepsis: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes.Clinical science (London, England : 1979) · 2026Article
- The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.Journal of internal medicine · 2026Review
- Prognostic impact of epicardial fat volume, anatomical and functional imaging across the cardiovascular risk spectrum in patients with suspected coronary artery disease: a single-center retrospective cohort study.Quantitative imaging in medicine and surgery · 2026Article
- Therapeutic Potential of Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicles in Atherosclerotic Stenosis and Endothelial Dysfunction.Cardiovascular drugs and therapy · 2026Article
- Hsa_circ_0044097 Serves as a Promising Biomarker of Atherosclerosis and Its Effects on Vascular Smooth Cell Proliferation and Migration.Journal of biochemical and molecular toxicology · 2026Article
- Article
- Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis.Internal and emergency medicine · 2026Review
- Device innovation or systemic risk management?-rethinking priorities in diabetic percutaneous coronary intervention.Cardiovascular diagnosis and therapy · 2026Article
- Long-term trends in metabolic profiles across Chinese birth cohorts: A real-world big data analysis.Clinical and translational medicine · 2026Article
- Enhanced functional mitochondrial donation through glucose-responsive antioxidant microcarrier-engineered native-like MSCs accelerates diabetic wound healing.Materials today. Bio · 2026Article
- EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach.Science advances · 2026Article
- Metal-Organic Framework as Contrast Agents for Magnetic Resonance Imaging.Pharmaceutics · 2026Review
- Sennoside A Ameliorates Diabetic Atherosclerosis by Inhibiting OSCP1/ERK1/2 Pathway to Regulate Endothelial Dysfunction.Chinese journal of integrative medicine · 2026Article
- Molecular Mechanisms Underlying the Comorbidity of Type 2 Diabetes Mellitus and Coronary Artery Disease: from Insulin Resistance and Inflammation to Endothelial Dysfunction and Therapeutic Implications.Cardiovascular drugs and therapy · 2026Review
- Fatty Kidney: The Interplay of Lipids and Diabetic Kidney Disease.Biomedicines · 2026Review
- Network Toxicology Reveals the Mechanisms of the Plasticizer Metabolite MECPP in Metabolic Diseases.International journal of molecular sciences · 2026Article
- Hexosamine Biosynthetic Pathway and Fatty Acid β-Oxidative Imbalance: A Key Mechanism by Which Abnormal Macrophage Lipophagy Promotes Atherosclerosis in Diabetes.Cardiovascular drugs and therapy · 2026Review
- A randomized controlled trial of drug-coated balloon versus conventional balloon angioplasty in diabetic patients with lower extremity arteriosclerosis obliterans: outcomes in ankle-brachial index and restenosis rate.Diabetology & metabolic syndrome · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a disease of large and medium arteries that can lead to life-threatening cardiovascular and cerebrovascular consequences, such as myocardial infarction and stroke. Moreover, atherosclerosis is a major contributor to cardiovascular-related mortality in individuals with diabetes mellitus. Diabetes aggravates the pathobiological mechanisms that underlie the development of atherosclerosis. Currently available anti-atherosclerotic drugs or strategies solely focus on optimal control of systemic risk factors, including hyperglycaemia and dyslipidaemia, but do not adequately target the diabetes-exacerbated mechanisms of atherosclerotic cardiovascular disease, highlighting the need for targeted, mechanism-based therapies. This Review focuses on emerging pathological mechanisms and related novel therapeutic targets in atherosclerotic cardiovascular disease in patients with diabetes.
Indexed as
Identifiers
39805949What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.